The complaint, City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., alleges that the animal health company concealed weakening prescription growth for its canine pain treatment, Librela, following FDA warnings regarding neurological complications. Further allegations suggest that the company’s dermatological staples, Apoquel and Cytopoint, along with the preventative Simparica Trio, faced significant market share erosion from lower-priced competitors that was not transparently disclosed to the market.
Investors Target Zoetis in Securities Fraud Class Action
A federal class action lawsuit filed in the Southern District of New York accuses Zoetis Inc. of misleading shareholders regarding the market performance of its flagship veterinary products. Investors who acquired ZTS securities between January 14, 2025, and May 6, 2026, now face a July 27, 2026, deadline to seek lead plaintiff status.
These concerns culminated on May 7, 2026, when Zoetis released its first-quarter financial results for the year. The data revealed a sharp decline in the company’s Companion Animal business, triggering a 21.5% drop in stock price. Law firm Kessler Topaz Meltzer & Check, LLP is currently evaluating claims for affected investors. Those seeking to serve as lead plaintiff must file their motion with the court by July 27, 2026, though investors may also choose to remain absent class members.
Comments (0)
No comments yet. Be the first!